Object

This publication is protected and available only for logged users.
This publication is protected and available only for logged users.

Title: Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors

Abstract:

Background. The aim of the study was to compare efficacy and tolerance of first-line palliative chemotherapy EOX (epirubicin/oxaliplatin/capecitabine) and mDCF (docetaxel/cisplatin/5FU/leucovorin) regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors.Methods. Each chemotherapy regimen was assigned with 21 patients. Planned treatment consisted of 12 every-two-weeks mDCF cycles or 8 every-three-weeks EOX cycles (24 weeks of treatment in each arm). The primary endpoint was overall survival in all patients who commenced at least one chemotherapy cycle.Results. Median progression-free survival was 5.8 months in EOX group and 7.5 months in mDCF group (p=0,11), and median overall survival was 8.5 months and 12.0 months respectively (p=0,219). In the EOX arm there were more frequent reductions of cytostatics doses (p=0,009) as well as delays in the administration of subsequent chemotherapy cycles (p=0,424). Rates of all grade 3 or 4 adverse events were comparable between both arms (p=1,000), however nausea (p=0,093), thromboembolic events (p=0,663) and grade 3 or 4 neutropenia (p=0,443) were more frequent in the EOX group.Conclusions. In patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors treatment with mDCF regimen is associated with a statistically non-significant 3.5 month longer median overall survival without increase in toxicity.

Place of publishing:

Kraków

Level of degree:

2 - studia doktoranckie

Degree discipline:

choroby układu trawiennego ; onkologia

Degree grantor:

Uniwersytet Jagielloński. Collegium Medicum. Wydział Lekarski.

Promoter:

Krzysztof Krzemieniecki

Date issued:

2014

Format:

application/pdf

Identifier:

oai:dl.cm-uj.krakow.pl:3935

Call number:

ZB-121240

ControlNumberVIRTUA:

click here to follow the link

Language:

pol

Access rights:

tylko w bibliotece

Location of original object:

Biblioteka Medyczna Uniwersytetu Jagiellońskiego- Collegium Medicum

Object collections:

Last modified:

Jun 26, 2019

In our library since:

Nov 26, 2014

Number of object content hits:

47

Number of object content views in PDF format

47

All available object's versions:

http://dl.cm-uj.krakow.pl:8080/publication/3935

Show description in RDF format:

RDF

Show description in OAI-PMH format:

OAI-PMH

Edition name Date
ZB-121240 Jun 26, 2019
×

Citation

Citation style:

This page uses 'cookies'. More information